Development of a live varicella vaccine - Past and future

Japanese Journal of Infectious Diseases

Volumn 53, Issue 2, 2000, Pages 47-55

  Takahashi, Michiaki ^a  

^a Osaka University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; LIVE VACCINE; NUCLEOTIDE;

ADENOVIRUS; AGED; ANIMAL CELL; BINDING AFFINITY; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETIC VARIABILITY; GUINEA PIG; HAMSTER; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMEDIATE EARLY GENE; MEASLES; NONHUMAN; NUCLEOTIDE SEQUENCE; POLIOMYELITIS VIRUS; POSTHERPETIC NEURALGIA; REVIEW; VARICELLA ZOSTER VIRUS; VIRUS ATTENUATION; VIRUS MUTANT; VIRUS STRAIN;

ANIMALS; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; CRICETINAE; EUROPE; GUINEA PIGS; HERPES ZOSTER; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; UNITED STATES;

EID: 0033925305     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Okuno, Y., Sugai, T., Fujita, T., Yamamura, T., Toyoshima, K., Takahashi, M., Nakamura, K. and Kunita, N. (1960): Studies on the prophylaxis of measles with attenuated living virus. Cultivation of measles virus isolated in tissue culture in developing chick egg. Biken J., 3, 107-113.
2. Okuno, Y., Takahashi, M., Toyosima, M., Yamamura, T., Sugai, T., Nakamura, K. and Kunita, N. (1960): Studies on the prophylaxis of measles with attenuated living virus. Inoculation tests in man and monkeys with chick embryo passage measles virus. Biken J., 3, 115-122.
3. Takahashi, M., Okabe, S. and Onaka, M. (1962): Studies on attenuation of poliovirus (type 3, Saukett strain) by modified passage in developing chick embryo and chick cell culture. Biken J., 5, 67-76.
4. Takahashi, M., Hamada, S. and Okabe, S. (1963): Characteristics of attenuated type 3 poliovirus obtained by alternate passage in chick cell cultures and monkey kidney cell cultures. Biken J., 6, 219-222.
5. Trentin, J. J., Yabe, Y. and Taylor, G. (1962): The quest for human cancer viruses. Science, 137, 835-849.
6. Takahashi, M. (1972): Isolation of conditional lethal mutants (temperature sensitive and host-dependent mutants) of adenovirus type 5. Virology, 49, 815-817.
7. Takahashi, M., Minekawa, Y. and Yamanishi, K. (1974): Transformation of a hamster embryo cell line (Nil) with a host-dependent mutant of adenovirus type 5. Virology, 57, 300-303.
8. Minekawa, Y., Ishibashi, M., Yasue, H. and Takahashi, M. (1976): Characterization of host-range and temperature sensitive mutants of adenovirus type 5 with particular regard to transformation of a hamster embryo cell line (Nil). Virology, 71, 97-110.
9. Duff, R. and Rapp, F. (1971): Oncogenic transformation of hamster cells after exposure to herpes simplex virus type 2. Nature, 233, 45-50.
10. Takahashi, M. and Yamanishi, K. (1974): Transformation of hamster and human embryo cells by temperature sensitive mutants of herpes simplex virus type 2. Virology, 61, 306-311.
11. GeLb, L., Huang, J. J. and Vellinghof, W. J. (1980): Varicella-zoster virus transformation of hamster embryo cells. J. Gen. Virol., 51, 171-177.
12. Gelb, L. and Dohner, D. (1984): Varicella-zoster virusinduced transformation of mammalian cells in vitro. J. Invest. Dermatol., 83, 77s-81s.
13. Caunt, A. E. (1963): Growth of varicella-zoster virus in human thyroid tissue cultures. Lancet, 2, 982-983.
14. Caunt, A. E. and Taylor-Robinson, D. (1964): Cell-free varicella-zoster virus in tissue culture. J. Hyg. (Lond.), 62, 413-424.
15. Brunell, P. A. (1967): Separation of infectious varicella-zoster virus from human embryonic lung fibroblasts. Virology, 31, 732-734.
16. Asano, Y. and Takahashi, M. (1978): Studies on neutralization of varicella-zoster virus and serological follow-up of cases of varicella and zoster. Biken J., 21, 15-23.
17. Takahashi, M., Otsuka, T., Okuno, Y., Asano, Y., Yazaki, T. and Isomura, S. (1974): Live vaccine used to prevent the spread of varicella in children in hospital. Lancet, 2, 1288-1290.
18. Takahashi, M., Asano, Y., Kamiya, H., Baba, K. and Yamanishi, K. (1981): Active immunization for varicella-zoster virus, p.414-431. In Nahmias, A. J., Dowdle, W.R. and Schinazi, R. F. (eds.), The Human Herpes Viruses: An Interdisciplinary Perspective. Elsevier, New York, USA.
19. Matsunaga, Y., Yamanishi, K. and Takahashi, M. (1982): Experimental infection and immune response of guinea pigs with varicella-zoster virus. Infect. Immun., 37, 407-412.
20. Hayakawa, Y., Torigoe, S., Shiraki, K., Yamanishi , K. and Takahashi, M. (1984): Biologic and biophysical markers of a live varicella vaccine strain (Oka): identification of clinical isolates from vaccine recipients. J. Infect. Dis., 149, 956-963.
21. Gomi, Y., Mori, T., Imagawa, T., Takahashi, M. and Yamanishi, K. (2000): Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity. J. Med. Virol., (in press).
22. Hayflick, L., Plotkin, S. and Stevenson, R. E. (1987): History of the acceptance of human diploid cell strains as substrates for human virus vaccine manufacture. Dev. Biol. Stand., 68, 9-17.
23. Jacobs, J. P. (1976): The status of human diploid cell strain MRC-5 as an approved substrate for the production of viral vaccines. J. Biol. Stand., 4, 97-99.
24. Asano, Y., Nakayama, H., Yazaki, T., Kato, R., Hirose, S., Tsuzuki, K., Ito, S., Isomura, S. and Takahashi, M. (1977): Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics, 59, 3-7.
25. Asano, Y., Nakayama, H., Yazaki, T., Ito, S., Isomura, S. and Takahashi, M. (1977): Protective efficacy of vaccination in children in four episodes of natural varicella and zoster in the ward. Pediatrics, 59, 8-12.
26. Asano, Y. and Takahashi, M. (1977): Clinical and serologic testing,of a live varicella vaccine and two-year follow-up for immunity of the vaccinated children. Pediatrics, 60, 810-814.
27. Baba, K., Yabuuchi, H., Okuni, H. and Takahashi, M. (1978): Studies with live varicella vaccine and inactivated skin test antigen: protective effect of the vaccine and clinical application of the skin test. Pediatrics, 61, 550-555.
28. Hattori, A., Ihara, T., Iwasa, T., Kamiya, H., Sakurai, M., Izawa, T. and Takahashi, M. (1976): Use of live varicella vaccine in children with acute leukemia or other malignancies. Lancet, 2, 210.
29. Izawa, T., Ihara, T., Hattori, A., Iwasa, T., Kamiya, H., Sakurai, M. and Takahashi, M. (1977): Application of a live varicella vaccine in children with acute leukemia or other malignant diseases. Pediatrics, 60, 805-809.
30. Brunell, P. A. (1977): Commentary: Protection against varicella. Pediatrics, 59, 1-2.
31. Sabin, A. B. (1977): Commentary: varicella-zoster virus vaccine. JAMA, 238, 1731-1733.
32. Plotkin, S. A. (1977): Varicella vendetta: Plotkin's plug. Pediatrics, 59, 953-954.
33. Brunell, P. A. (1977): Brunell's brush-off. Pediatrics, 59, 954.
34. Kempe, C. H. and Gershon, A. A. (1977): Commentary: varicella vaccine at the crossroads. Pediatrics, 60, 930-931.
35. Gershon, A. A., Steinberg, S. P., Gelb, L., Galasso, G., Borkowski, W., LaRussa, P., Ferrera, A. and NIAID Varicella Vaccine Collaborative Study Group (1984): Live varicella vaccine: efficacy for children with leukemia in remission. JAMA, 252, 355-362.
36. Lawrence, R., Gershon, A. A., Holzman, R., Steinberg, S. P. and NIAID Varicella Vaccine Collaborative Study Group (1988): The risk of zoster after varicella vaccination in children with leukemia. N. Engl. J. Med., 318, 543-548.
37. Gershon, A. A., Steinberg, S. and NIAID Collaborative Varicella Vaccine Study Group (1989): Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N. Engl. J. Med., 320, 892-897.
38. Tsolia, M., Gershon, A., Steinberg, S. and NIAID Collaborative Study Group (1990): Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. J. Pediatr., 116, 184-189.
39. Brunell, P. A., Shehab, Z., Geiser, C. and Waugh, J. E. (1982): Administration of live varicella vaccine to children with leukemia. Lancet, 2, 1069-1073.
40. Arbeter, A., Starr, S., Weibel, R. E. and Plotkin, S. A. (1982): Live attenuated varaicella vaccine: immunization of healthy children with the Oka strain. J. Pediatr., 100, 886-893.
41. Weibel, R., Neff, B. J., Kuter, B. J., Guess, H. A., Rothenberger, C. A., Fitzgerald, A. J., Connor, K. A., McLean, A. A., Hilleman, M. R. and Buynak, F. B. (1984):Live attenuated varicella virus vaccine: efficacy trial in healthy children. N. Engl. J. Med, 310, 1409-1415.
42. Arbeter, A. M., Starr, S. E., Preblud, S., Ihara, T., Paciorek, T., Miller, D. S., Zelson, C. M., Proctor, E. A. and Plotkin, S. (1984): Varicella vaccine follow-up studies. Am. J. Dis. Child., 138, 434-438.
43. Diaz, P. S., Au, D., Smith, S., Amylon, M., Link, M., Smith, S. and Arvin, A. M. (1991): Lack of transmission of the live attenuated varicella vaccine to immunocompromised children after immunization of their siblings. Pediatrics, 87, 166-170.
44. WHO Expert Committee of Biological Standardization (1985): Requirements for varicella vaccine (live). p. 102-133. Requirements for Biological Substances No. 36, WHO, Geneva.
45. Symposium (1985): Active immunization against varicella. Proceeding of a symposium held at Munich, Nov. 29-30, 1984. Postgrad. Med. J., 61 (suppl. 4), 3-168.
46. Plotkin, S. A., Arbeter, A. A. and Starr, S. E. (1985): The future of varicella vaccine. Postgrad. Med. J., 61 (suppl. 4), 155-162.
47. Hope-Simpson, R. E. (1965): The nature of herpes zoster: a long term study and a new hypothesis. Proc. R. Soc. Med., 58, 9-20.
48. Kamiya, H., Kato, T., Isaji, M., Oitani, K., Ito, M., Ihara, T., Sakurai, M. and Takahashi, M. (1984): Immunization of acute leukemic children with a live varicella vaccine. Biken J., 27, 99-102.
49. Yabuuchi, H., Baba, H., Tsuda, N., Okada, S., Nose, O., Seino, T., Tomita, K., Ha, K., Mimaki, T., Ogawa, M., Kanesaki, T., Yoshida, M. and Takahashi, M. (1984): A live varicella vaccine in a pediatric community. Biken J., 27, 43-49.
50. Takahashi, M. (1986): Varicella vaccine. Pediatr. Clin., 49, 1941-1949 (in Japanese).
51. Takahashi, M. (1986): Development and characterization of varicella vaccine. Clin. Virol., 14 (suppl.), 74-79 (in Japanese).
52. Takahashi, M. (1987): A vaccine to prevent chickenpox. p. 179-209. In Hyman, R.W. (ed.), Natural History of Varicella-Zoster Virus. CRC Press, Boca Raton, Fla., USA.
53. Takahashi, M., Baba, K., Horiuchi, K., Kamiya, H. and Asano, Y. (1990): A live varicella vaccine. Adv. Exp. Med. Biol., 278, 49-58.
54. Brunell, P.A., Taylor-Wiedeman, J., Geiser, C. F., Frieson, L. and Lydick, E. (1986): Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics, 77, 53-56.
55. Hardy, I. B., Gershon, A. A., Steinberg, S. P., LaRussa, P. and Varicella Vaccine Collaborative Study Group (1991): The incidence of zoster after immunization with live attenuated vaccine. A study in children with leukemia. N. Engl. J. Med., 325, 1545-1550.
56. Johnson, R. T. and Mims, C. A. (1968): Pathogenesis of viral infections of the nervous system. N. Engl. J. Med., 278, 23-30.
57. Asano, Y., Itakura, N., Hiroishi, Y., Hirose, S., Ozaki, T., Kuno, T., Nagai, T., Yazaki, T., Yamanishi, K. and Takahashi, M. (1985): Viral replicaiton and immunologic responses in children naturally infected with varicella-zoster virus and in varicella vaccine recipients. J. Infect. Dis., 152, 863-868.
58. Ragozzino, M. W., Melton, L. J., Kurland, L. T., Chu, C. P. and Perry, H. O. (1982): Population-based study of herpes zoster and its sequelae. Medicine, 61, 310-316.
59. Levin, M. J. and Hayward, A. R.(1996): Prevention of herpes zoster. Infect. Dis. Clin. North Am., 10, 657-675.
60. Levin, M. J., Barber, D., Goldblatt, E., Jones, M., LaFleur, B., Chan, C., Stinson, D., Zerbe, G. O. and Hayward, A. R. (1998): Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J. Infect. Dis., 178 (suppl. 1), S109-S112.
61. Takahashi, M. and Yamanishi, K. (2000): Immunization of the eldery to boost immunity against VZV assessed by VZV skin test. (Proceeding of International Conference on Immunity and Prevention of Herpes Zoster. Osaka, March 8-10, 1999) Arch. Virol., (in press).